Corvus Pharmaceuticals Statistics
Total Valuation
CRVS has a market cap or net worth of $276.29 million. The enterprise value is $233.23 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRVS has 68.14 million shares outstanding. The number of shares has increased by 37.23% in one year.
| Current Share Class | 68.14M |
| Shares Outstanding | 68.14M |
| Shares Change (YoY) | +37.23% |
| Shares Change (QoQ) | +9.96% |
| Owned by Insiders (%) | 4.30% |
| Owned by Institutions (%) | 37.26% |
| Float | 51.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.60 |
| P/TBV Ratio | 5.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.90, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.90 |
| Quick Ratio | 4.77 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -100.13% and return on invested capital (ROIC) is -45.97%.
| Return on Equity (ROE) | -100.13% |
| Return on Assets (ROA) | -39.21% |
| Return on Invested Capital (ROIC) | -45.97% |
| Return on Capital Employed (ROCE) | -62.24% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.34M |
| Employee Count | 31 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +94.95% in the last 52 weeks. The beta is 0.66, so CRVS's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | +94.95% |
| 50-Day Moving Average | 3.68 |
| 200-Day Moving Average | 5.26 |
| Relative Strength Index (RSI) | 59.31 |
| Average Volume (20 Days) | 1,589,514 |
Short Selling Information
The latest short interest is 5.77 million, so 8.47% of the outstanding shares have been sold short.
| Short Interest | 5.77M |
| Short Previous Month | 5.34M |
| Short % of Shares Out | 8.47% |
| Short % of Float | 11.19% |
| Short Ratio (days to cover) | 6.48 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -31.22M |
| Pretax Income | n/a |
| Net Income | -41.40M |
| EBITDA | -31.13M |
| EBIT | -31.22M |
| Earnings Per Share (EPS) | -$0.99 |
Full Income StatementBalance Sheet
The company has $44.21 million in cash and $1.15 million in debt, giving a net cash position of $43.06 million or $0.63 per share.
| Cash & Cash Equivalents | 44.21M |
| Total Debt | 1.15M |
| Net Cash | 43.06M |
| Net Cash Per Share | $0.63 |
| Equity (Book Value) | 49.33M |
| Book Value Per Share | 0.72 |
| Working Capital | 36.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.53 million and capital expenditures -$36,000, giving a free cash flow of -$28.57 million.
| Operating Cash Flow | -28.53M |
| Capital Expenditures | -36,000 |
| Free Cash Flow | -28.57M |
| FCF Per Share | -$0.42 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |